RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data
G Kafatos, D Niepel, K Lowe… - Biomarkers in …, 2017 - Taylor & Francis
Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-
EGFR treatment for metastatic colorectal cancer. This noninterventional, observational …
EGFR treatment for metastatic colorectal cancer. This noninterventional, observational …
[HTML][HTML] Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled …
M Peeters, G Kafatos, A Taylor, VM Gastanaga… - European journal of …, 2015 - Elsevier
Background The use of epidermal growth factor receptor inhibitors to treat metastatic
colorectal cancer (mCRC) patients requires prior confirmation of tumour wild type (WT) RAS …
colorectal cancer (mCRC) patients requires prior confirmation of tumour wild type (WT) RAS …
RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres
A Boleij, V Tack, A Taylor, G Kafatos… - BMC cancer, 2016 - Springer
Background Treatment options for patients with metastatic colorectal cancer (mCRC) include
anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS …
anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS …
[HTML][HTML] RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
A Boleij, BBJ Tops, PDM Rombout, EM Dequeker… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract In 2013 the European Medicine Agency (EMA) restricted the indication for anti-
EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene …
EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type RAS gene …
RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014
A Lièvre, JL Merlin, JC Sabourin, P Artru, S Tong… - Digestive and Liver …, 2018 - Elsevier
Abstract Background RAS (NRAS+ KRAS) mutation testing is required in addition to simple
KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies …
KRAS testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies …
[HTML][HTML] Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer
An external file that holds a picture, illustration, etc. Object name is bi-11-5-g003. jpg
Introduction: Early-activated RAS/RAF mutation status is a key molecular finding in …
Introduction: Early-activated RAS/RAF mutation status is a key molecular finding in …
Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients
A Muendlein, K Geiger, C Heinzle, S Gaenger… - Journal of Cancer …, 2023 - Springer
Purpose RAS mutations are predictors of an adverse outcome in EGFR-targeted therapies
and have been proposed as prognostic biomarkers of survival in metastatic colorectal …
and have been proposed as prognostic biomarkers of survival in metastatic colorectal …
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
C Santos, D Azuara, R Garcia-Carbonero… - Molecular Cancer …, 2017 - AACR
In metastatic colorectal cancer (mCRC), recent studies have shown the importance to
accurately quantify low-abundance mutations of the RAS pathway because anti-EGFR …
accurately quantify low-abundance mutations of the RAS pathway because anti-EGFR …
[HTML][HTML] Concordance of blood-and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
J Grasselli, E Elez, G Caratù, J Matito, C Santos… - Annals of …, 2017 - Elsevier
ABSTRACT Background Circulating tumor DNA (ctDNA) is a potential source for tumor
genome analysis. We explored the concordance between the mutational status of RAS in …
genome analysis. We explored the concordance between the mutational status of RAS in …
Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2
N Boeckx, M Peeters, G Van Camp, P Pauwels… - Drugs, 2015 - Springer
The advent of anti-EGFR (epidermal growth factor receptor) therapy resulted in significant
progress in the treatment of metastatic colorectal cancer patients. However, many patients …
progress in the treatment of metastatic colorectal cancer patients. However, many patients …